Abstract: A tablet comprises a granulate of an active pharmaceutical ingredient comprising at least one cannabinoid having a melting point less than about 80° C.; sugar, sugar alcohol, or a combination thereof; microcrystalline cellulose having an average particle size less than about 25 ?m; silica, silicified microcrystalline cellulose, or a combination thereof; and lubricant comprising sodium stearyl fumarate and lecithin. Methods of forming such a tablet using direct compression of a tablet formulation can be conducted on a large manufacturing scale.

Abstract: A method for formulating an active pharmaceutical ingredient (API) comprises mixing the API and micronized polymer matrix particles comprising polymer strands and having a mean geometric particle diameter in a range of from about 0.1 to about 100 microns, wherein the API is in a liquid phase, to form a homogeneous slurry, allowing the polymer matrix particles to absorb the API, and drying the slurry to form a composite material. The composite material facilitates formation of a tablet or other solid unit dosage form containing the API and/or improves dissolution of the API, for example, in vivo.

Abstract: Dry powders comprise a cannabinoid, a polymer binding agent, a dispersing agent, and a bulking agent, and optionally an antioxidant, and are formed by carbon dioxide-assisted nebulization and drying in a flowing dry stream of gas. The dry powders have an aerodynamic particle distribution effective for delivery by respiration into the lungs of a patient. Methods of preparing a dry powder comprise subjecting a solution of a volatile component, a cannabinoid, a polymer binding agent, a dispersing agent, and a bulking agent, and optionally an antioxidant, to carbon dioxide-assisted nebulization, and drying droplets formed by the nebulization in a flowing dry gas stream to form a dry powder. The dry powder has an aerodynamic particle distribution effective for delivery of the dry powder by respiration into a lung of a patient and/or exhibit increased bioavailability and/or storage stability of a cannabinoid. The dry powder can be compressed into a wafer.

Abstract: A purified cannabidiol (CBD) extract and/or cannabidiolic acid (CBDA) extract is isolated from industrial hemp and comprises less than 0.5 wt % organic impurities as measured by HPLC and 1H NMR spectroscopy exhibits no detectable peak at 4.07 ppm as measured by 1H NMR spectroscopy. The CBD and/or CBDA extract is in crystalline form. The CBD extract exhibits a melting point as measured by differential scanning calorimetry (DSC) of 69-70° C. Dry powder compositions comprise such extracts. Additional dry powder compositions comprise polyvinylpyrrolidone and an amorphous CBD extract. An adduct comprises CBD and/or CBDA bonded to a paramagnetic trivalent lanthanide (III) metal chelate.